Abstract
Doxorubicin is one of the most potent anti-tumor agents used generally in the treatment of bone cancer. Like other cancer chemotharepeutics, it produces undesirable side effects such as cardiotoxicity, which is especially severe when administrated via the conventional intravenous route. In order to minimize the systemic toxicities and to make this drug more suitable for the treatment of bone cancer, an implantable delivery system with cross-linked gelatin as the biodegradable matrix material was developed. This delivery system could possibly improve targeting of the drug as well as sustain the rate of release of the drug to the tumor. Glutaraldehyde was used as a cross-linking agent. Incorporation of glutaraldehyde in the matrix was needed to maintain the mechanical strength of the implant and to sustain the rate of release of the drug from the implant. Besides cross-linking the gelatin matrix, glutaraldehyde was found to cross-link the free amino group of doxorubicin. The effect of cross-linker concentration on the stability of the drug in the implant and on the rate and extent of release were also evaluated. In conclusion, cross-linked gelatin implants were developed for the local delivery of doxorubicin.
| Original language | English |
|---|---|
| Pages (from-to) | 103-116 |
| Number of pages | 14 |
| Journal | International Journal of Pharmaceutics |
| Volume | 213 |
| Issue number | 1-2 |
| DOIs | |
| State | Published - Feb 1 2001 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmaceutical Science
Cite this
Effect of cross-linking on the in vitro release kinetics of doxorubicin from gelatin implants. / Fan, Haiyun; Dash, Alekha K.
In: International Journal of Pharmaceutics, Vol. 213, No. 1-2, 01.02.2001, p. 103-116.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of cross-linking on the in vitro release kinetics of doxorubicin from gelatin implants
AU - Fan, Haiyun
AU - Dash, Alekha K.
PY - 2001/2/1
Y1 - 2001/2/1
N2 - Doxorubicin is one of the most potent anti-tumor agents used generally in the treatment of bone cancer. Like other cancer chemotharepeutics, it produces undesirable side effects such as cardiotoxicity, which is especially severe when administrated via the conventional intravenous route. In order to minimize the systemic toxicities and to make this drug more suitable for the treatment of bone cancer, an implantable delivery system with cross-linked gelatin as the biodegradable matrix material was developed. This delivery system could possibly improve targeting of the drug as well as sustain the rate of release of the drug to the tumor. Glutaraldehyde was used as a cross-linking agent. Incorporation of glutaraldehyde in the matrix was needed to maintain the mechanical strength of the implant and to sustain the rate of release of the drug from the implant. Besides cross-linking the gelatin matrix, glutaraldehyde was found to cross-link the free amino group of doxorubicin. The effect of cross-linker concentration on the stability of the drug in the implant and on the rate and extent of release were also evaluated. In conclusion, cross-linked gelatin implants were developed for the local delivery of doxorubicin.
AB - Doxorubicin is one of the most potent anti-tumor agents used generally in the treatment of bone cancer. Like other cancer chemotharepeutics, it produces undesirable side effects such as cardiotoxicity, which is especially severe when administrated via the conventional intravenous route. In order to minimize the systemic toxicities and to make this drug more suitable for the treatment of bone cancer, an implantable delivery system with cross-linked gelatin as the biodegradable matrix material was developed. This delivery system could possibly improve targeting of the drug as well as sustain the rate of release of the drug to the tumor. Glutaraldehyde was used as a cross-linking agent. Incorporation of glutaraldehyde in the matrix was needed to maintain the mechanical strength of the implant and to sustain the rate of release of the drug from the implant. Besides cross-linking the gelatin matrix, glutaraldehyde was found to cross-link the free amino group of doxorubicin. The effect of cross-linker concentration on the stability of the drug in the implant and on the rate and extent of release were also evaluated. In conclusion, cross-linked gelatin implants were developed for the local delivery of doxorubicin.
UR - http://www.scopus.com/inward/record.url?scp=0035253417&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035253417&partnerID=8YFLogxK
U2 - 10.1016/S0378-5173(00)00651-7
DO - 10.1016/S0378-5173(00)00651-7
M3 - Article
C2 - 11165098
AN - SCOPUS:0035253417
VL - 213
SP - 103
EP - 116
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
SN - 0378-5173
IS - 1-2
ER -